TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q3 2026 Revenue of $17.2 Million, TONMYA Sales Growth of 37%
Tonix Pharmaceuticals (NASDAQ: TNXP) announced financial results for the third quarter ended Sept. 30, 2026, reporting net product revenue of approximately $17.2 million, compared with $3.3 million in the prior-year period. Revenue included $15 million from TONMYA, representing a 37% increase over the second quarter. Total prescriptions rose 28% quarter over quarter to 16,375, while new prescriptions increased 17% and refills climbed 56%. TONMYA coverage expanded to approximately 166 million lives, and the company increased its sales force to approximately 150 representatives. Tonix reported a net loss available to common stockholders of $53.3 million, or $2.89 per share, compared with…

